NISTmAb, the world's first standardized monoclonal antibody has become a valuable tool for biomanufacturers developing new biologic therapies for cancers, autoimmune disorders and infectious diseases. Although the molecule has been precisely characterized, the current proprietary method for its production has not. In a new article, researchers describe how they have taken the first step to solve this dilemma: engineering three mouse cell lines to produce nonproprietary versions of NISTmAb that closely resemble the characteristics of the original reference material.
from Top Health News -- ScienceDaily https://ift.tt/2mYipz7
the news of the day, for today, top news of today, world news today live, top local news, top news stories of the day, top news today in the world, news today nyc, top news today local,
Subscribe to:
Post Comments (Atom)
A woman met a group of migrants at a school bus stop. Then the story hit the internet
from Yahoo News - Latest News & Headlines https://ift.tt/nkAV0rJ
-
from Yahoo News - Latest News & Headlines https://ift.tt/m2VMCS1
-
from Yahoo News - Latest News & Headlines https://ift.tt/jYPuwNf
-
from Yahoo News - Latest News & Headlines https://ift.tt/Ot2Ebrh
No comments:
Post a Comment